The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary

Oncology Letters

Volumn 2, Issue 4, 2011, Pages 591-597

  Shigetomi, Hiroshi ^a   Oonogi, Akira ^a   Tsunemi, Taihei ^a   Tanase, Yasuhito ^a   Yamada, Yoshihiko ^a   Kajihara, Hirotaka ^a   Yoshizawa, Yoriko ^a   Furukawa, Naoto ^a   Haruta, Shoji ^a   Yoshida, Shozo ^a   Sado, Toshiyuki ^a   Oi, Hidekazu ^a   Kobayashi, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adenine thymine rich interactive domain 1A; Chromatin; Clear cell carcinoma of the ovary

Indexed keywords

ADENINE; ADENINE THYMINE RICH INTERACTIVE DOMAIN 1A; HISTONE H2B; PLATINUM DERIVATIVE; PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; TAXANE DERIVATIVE; THYMINE; UNCLASSIFIED DRUG;

CARCINOGENESIS; CELL CYCLE; CHROMATIN STRUCTURE; CLEAR CELL CARCINOMA; DNA DAMAGE; ENDOMETRIOSIS; FEMALE; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; OVARY CARCINOMA; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN FAMILY; REVIEW; UBIQUITINATION;

EID: 79958042328     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.316     Document Type: Review

References (54)

1. Piver MS: Prophylactic oophorectomy: reducing the U.S. death rate from epithelial ovarian cancer. A continuing debate. Oncologist 1: 326-330, 1996.
2. Kennedy AW, Biscotti CV, Hart WR and Webster KD: Ovarian clear cell adenocarcinoma. Gynecol Oncol 32: 342-349, 1998.
3. Ryu SY, Park SI, Nam BH, et al: Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group. Ann Oncol 20: 1032-1036, 2009.
4. Viganó P, Somigliana E, Chiodo I, Abbiati A and Vercellini P: Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. Hum Reprod Update 12: 77-89, 2006.
5. Kobayashi H, Sumimoto K, Moniwa N, et al: Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 17: 37-43, 2007.
6. Bell DA: Origins and molecular pathology of ovarian cancer. Mod Pathol 18 (Suppl 2): S19-S32, 2005.
7. Jiang X, Hitchcock A, Bryan EJ, et al: Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res 56: 3534-3539, 1996.
8. Kobayashi H, Kajiwara H, Kanayama S, et al: Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (Review). Oncol Rep 22: 233-240, 2009.
9. Yoo AS and Crabtree GR: ATP-dependent chromatin remodeling in neural development. Curr Opin Neurobiol 19: 120-126, 2009.
10. Weissman B and Knudsen KE: Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res 69: 8223-8230, 2009.
11. Osipovich OA, Subrahmanyam R, Pierce S, Sen R and Oltz EM: Cutting edge: SWI/SNF mediates antisense Igh transcription and locus-wide accessibility in B cell precursors. J Immunol 183: 1509-1513, 2009.
12. Kundu S and Peterson CL: Role of chromatin states in transcriptional memory. Biochim Biophys Acta 1790: 445-455, 2009.
13. Rodriguez-Nieto S and Sanchez-Cespedes M: BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer. Carcinogenesis 30: 547-554. 2009.
14. Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414, 2009.
15. Toyota M and Suzuki H: Epigenetic drivers of genetic alterations. Adv Genet 70: 309-323, 2010.
16. Fan D, Ma C and Zhang H: The molecular mechanisms that underlie the tumor suppressor function of LKB1. Acta Biochim Biophys Sin (Shanghai) 41: 97-107, 2009.
17. Hess J, Angel P and Schorpp-Kistner M: AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117: 5965-5973, 2004.
18. Hydbring P and Larsson LG: Cdk2: a key regulator of the senescence control function of Myc. Aging 2: 244-250, 2010.
19. Bogliolo M, Cabré O, Callén E, et al: The Fanconi anaemia genome stability and tumour suppressor network. Mutagenesis 17: 529-538, 2002.
20. Sansam CG and Roberts CW: Epigenetics and cancer: altered chromatin remodeling via Snf5 loss leads to aberrant cell cycle regulation. Cell Cycle 5: 621-624, 2006.
21. Watanabe H, Mizutani T, Haraguchi T, et al: SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines. Oncogene 25: 470-479, 2006.
22. Luo B, Cheung HW, Subramanian A, et al: Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 105: 20380-20385, 2008.
23. Crow E, Du Z and Li L: New insights into prion biology from the novel [SWI+] system. Prion 2: 141-144, 2008.
24. Mertens F, Johansson B, Höglund M and Mitelman F: Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res 57: 2765-2780, 1997.
25. Nagl NG Jr, Patsialou A, Haines DS, et al: The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res 65: 9236-9244, 2005.
26. Wang X, Nagl NG Jr, Flowers S, et al: Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. Int J Cancer 112: 636, 2004.
27. Wiegand KC, Shah SP, Al-Agha OM, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543, 2010.
28. Jones S, Wang TL, Shih IeM, et al: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231, 2010.
29. Wilsker D, Patsialou A, Dallas PB and Moran E: ARID proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth Differ 13: 95-106, 2002.
30. Li XS, Trojer P, Matsumura T, Treisman JE and Tanese N: Mammalian SWI/SNF - a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B. Mol Cell Biol 30: 1673-1688, 2010.
31. Gilbert PM, Mouw JK, Unger MA, et al: HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest 120: 1535-1550, 2010.
32. Dehennaut V and Leprince D: Implication of HIC1 (hypermethylated in cancer 1) in the DNA damage response. Bull Cancer 96: E66-E72, 2009.
33. Van Rechem C, Boulay G and Leprince D: HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A. Biochem Biophys Res Commun 385: 586-590, 2009.
34. Iaquinta PJ and Lees JA: Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 19: 649-657, 2007.
35. Ma K, Araki K, Ichwan SJ, et al: E2FBP1/DRIL1, an AT-rich interaction domain-family transcription factor, is regulated by p53. Mol Cancer Res 1: 438-444, 2003.
36. Kim YT and Zhao M: Aberrant cell cycle regulation in cervical carcinoma. Yonsei Med J 46: 597-613, 2005.
37. Bourdon JC: p53 and its isoforms in cancer. Br J Cancer 97: 277-282, 2007.
38. Staehling-Hampton K, Ciampa PJ, Brook A and Dyson N: A genetic screen for modifiers of E2F in Drosophila melanogaster. Genetics 153: 275-287, 1999.
39. Roesch A, Mueller AM, Stempfl T, et al: RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells. Int J Cancer 122: 1047-1057, 2008.
40. Zorn KK, Bonome T, Gangi L, et al: Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11: 6422-6430, 2005.
41. Gnarra JR, Tory K, Weng Y, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90, 1994.
42. Hacker KE, Lee CM and Rathmell WK: VHL type 2B mutations retain VBC complex form and function. PLoS One 3: E3801, 2008.
43. Vodermaier HC: APC/C and SCF: controlling each other and the cell cycle. Curr Biol 14: R787-R796, 2004.
44. Clark PE: The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int 76: 939-945, 2009.
45. Beisel C, Imhof A, Greene J, Kremmer E and Sauer F: Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1. Nature 419: 857-862, 2002.
46. Ezhkova E and Tansey WP: Proteasomal ATPases link ubiquitylation of histone H2B to methylation of histone H3. Mol Cell 13: 435-442, 2004.
47. Atanassov BS, Koutelou E and Dent SY: The role of deubiquitinating enzymes in chromatin regulation. FEBS Lett: Oct 26, 2010 (Epub ahead of print).
48. Dalgliesh GL, Furge K, Greenman C, et al: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360-363, 2010.
49. Wang JK, Tsai MC, Poulin G, et al: The histone demethylase UTX enables RB-dependent cell fate control. Genes Dev 24: 327-332, 2010.
50. Newbold RF and Mokbel K: Evidence for a tumour suppressor function of SETD2 in human breast cancer: a new hypothesis. Anticancer Res 30: 3309-3311, 2010.
51. Duns G, van den Berg E, van Duivenbode I, et al: Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res 70: 4287-4291, 2010.
52. Kurman RJ and Shih IeM: Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27: 151-160, 2008.
53. Kajihara H, Yamada Y, Kanayama S, et al: Clear cell carcinoma of the ovary: Potential pathogenic mechanisms (Review). Oncol Rep 23: 1193-1203, 2010.
54. Sufan RI, Jewett MA and Ohh M: The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol 287: F1-F6, 2004.